Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/49509

In Collections

This item can be found in the following collections:

Droog, M. (2017)

The effects of breast cancer therapy on estrogen receptor signaling throughout the body

Doctoral Thesis
Upon activation by estrogen, the Estrogen Receptor binds the chromatin and influences gene transcription. This ultimately leads to cell proliferation. About 75% of breast cancer patients express this hormonal receptor. These patients are often treated with tamoxifen, which competitively inhibits the proliferative effects of estrogen in breast cancer cells.
While tamoxifen inhibits the tumor growth of breast cancer, its effects in other Estrogen Receptor-positive tissues vary, as reviewed in chapter 1. Its most adverse side-effect is that it increases the risk for endometrial cancer. Chapters 2 and 3 describe the effects of tamoxifen on the DNA binding sites of the Estrogen Receptor in tamoxifen-associated endometrial cancer, and the similarities of these binding sites with those found in breast cancer.
Unfortunately, there are Estrogen Receptor...Show more

Upon activation by estrogen, the Estrogen Receptor binds the chromatin and influences gene transcription. This ultimately leads to cell proliferation. About 75% of breast cancer patients express this hormonal receptor. These patients are often treated with tamoxifen, which competitively inhibits the proliferative effects of estrogen in breast cancer cells.
While tamoxifen inhibits the tumor growth of breast cancer, its effects in other Estrogen Receptor-positive tissues vary, as reviewed in chapter 1. Its most adverse side-effect is that it increases the risk for endometrial cancer. Chapters 2 and 3 describe the effects of tamoxifen on the DNA binding sites of the Estrogen Receptor in tamoxifen-associated endometrial cancer, and the similarities of these binding sites with those found in breast cancer.
Unfortunately, there are Estrogen Receptor-positive breast cancer patients who do not respond to hormonal treatment. Chapter 4 reveals a key-role for activating transcription factor 2 on tamoxifen’s inhibitory response on cell proliferation. Chapter 5 discusses components of the Estrogen Receptor pathway and highlights their potential as biomarkers in hormonal response therapy.
Finally, chapter 6 provides new questions invoked by this thesis, and discusses the importance of unraveling the Estrogen Receptor pathway in multiple tissues in order to develop tailor-made treatments.

 

Show less
Estrogen receptor
Endocrine therapy
Tamoxifen
ChIP-seq
Breast cancer
Endometrial cancer
All authors
Droog, M.
Supervisor
Neefjes, J.J.C.
Co-supervisor
Zwart, W.T.
Committee
Caroll, J.S.; Jonkers, J.; Linn, S.C.; Maarel, S.M. van der; Wessels, L.F.A.
Qualification
Doctor (dr.)
Awarding Institution
Medicine, Leiden University
Date
2017-06-08
ISBN (print)
9789462996106

Funding

Sponsorship
Pink Ribbon; KWF Dutch Cancer Society, the Netherlands; Organisation of Scientific Research (NWO), Top Institute Pharma, A Sister's Hope